Netherlands: Health Secy Visits Bilthoven Biologicals, Discusses Collaboration On Production Of Oral Polio Vaccine

New Delhi: Union Health Secretary Apurva Chandra on Wednesday visited the manufacturing unit of global pharmaceutical company Bilthoven Biologicals at Utrecht, Netherlands.

Further, the Union Health Secretary met with CEO Juergen Kwik and CEO of Poonawalla Science Park (PSP) at Bilthoven Jef De Clercq on EU pandemic preparedness partnership and collaboration on production of vaccines, the Ministry of Health and FamilyWelfare said in a Press release.

“She also met the senior management and was briefed on the various manufacturing units of the facility. A detailed presentation was made on their future manufacturing plans. Bilthoven Biologicals BV Co manufactures pharmaceutical products such as vaccines for polio, diphtheria-tetanus-polio, and tetanus along with bacillus calmette-guerin (BCG) ,” the press release added.

The bioengineering and vaccine production firm Bilthoven Biologicals was purchased by Serum India Ltd., in 2012. This has strengthened its capacity of producing vaccines and also provided it with a valuable manufacturing base in Europe.

Recently Serum and Bharat Biotech have announced collaboration for enhanced production of OPV. Bharat Biotech will collaborate with Netherlands-based Bilthoven Biologicals BV, a wholly-owned arm of Serum Institute of India.

According to a press release, an agreement has been signed under which Bharat Biotech will procure drug substances for manufacturing oral polio vaccines to be supplied within India and globally. This will contribute to supply security of oral polio vaccines. With this partnership, the capacity of BBIL to manufacture Oral Polio Vaccine (OPV) has increased to 500 million doses every year.

Universal Immunisation Programme (UIP) of the Union Health Ministry is one of the key interventions for protection of children from life threatening conditions by providing vaccination, including vaccine against polio. India has been certified free of Polio in March 2014.However, to maintain the polio-free status, polio vaccine is given to children as part of the high quality national and sub-national polio rounds across the country.

A sustained supply of OPV is essential for keeping India polio free. The partnership between BBIL and Serum will contribute to providing a sustained supply of OPV in the country.

Related Posts

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna: In a significant ruling that could have far-reaching implications for NDPS drug-related prosecutions involving common pharmaceutical compounds, the Patna High Court has held that Phenothiazine and Promethazine do not…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines